Diffuse large B-cell lymphoma (DLBCL) is the most common and fast-growing type of non-Hodgkin lymphoma, a cancer that affects ...

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and ...

Australian patients with the most common form of lymphoma will for the first time have access to affordable, at-home treatment options after the federal subsidisation of an injectable immunotherapy.

in 83% of patients with indolent relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) comparing favorably to 34% historical CR rate with R 2 alone - Phase 2 portion of trial in patients with ...

The first patient with relapsed or refractory CD5-positive T-cell lymphoma has been dosed with the CAR-T cell therapy MB-105.

Expert Rev Anticancer Ther. 2009;9(9):1305-1316. Very recently, the addition of bortezomib to chemotherapy was evaluated in DLBCL patients relapsing after R-CHOP. [49] To test the hypothesis that ...

Monoclonal antibodies like rituximab revolutionized non-Hodgkin lymphoma treatment by targeting the CD20 protein found on B-cell lymphomas. This targeted approach improved survival rates while ...

A new independent academic study examining a form of blood cancer among those who served at Malmstrom Air Force Base, Montana ...

In part 4 of an interview with The American Journal of Managed Care®, Frederick L. Locke, MD, provides insight on the design ...